Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antihypertensive Agents Clear all
Completed Not applicable Interventional

Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis

NCT03327909
View directory record Official record
Conditions
ESRD, Hemodialysis Complication, Blood Pressure
Interventions
TAKE vs. HOLD
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Menlo Park, California • San Carlos, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Implementing Evidence Based Treatment of Hypertension

NCT00265538
View directory record Official record
Conditions
Hypertension
Interventions
Patient educational letter to engage provider in hypertension rx discussion, Financial incentive (Arms B and C) and health educator phone call (Arm C)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Iowa City, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764
View directory record Official record
Conditions
Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions
Lisinopril, Hydrochlorothiazide
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

NCT00887510
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making

NCT03156634
View directory record Official record
Conditions
Patient Education
Interventions
PALS, WebMD
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

NCT01195662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children

NCT00178490
View directory record Official record
Conditions
Hypertension
Interventions
High blood pressure treatment
Drug
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 2, 2026, 4:10 AM EDT
Completed No phase listed Observational

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

NCT04354350
View directory record Official record
Conditions
Hypertension
Interventions
Ramipril, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
63,744 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Not applicable Interventional

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

NCT05676476
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy
Interventions
Antihypertensive treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 49 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 2, 2026, 4:10 AM EDT
Not yet recruiting Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

NCT00978822
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Hypertension
Interventions
Clevidipine butyrate injectable emulsion
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524
View directory record Official record
Conditions
Essential Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 2, 2026, 4:10 AM EDT
Recruiting Phase 4 Interventional

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

NCT06246396
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Minocycline Hydrochloride, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Active, not recruiting Phase 3 Interventional

Preeclampsia Postpartum Antihypertensive Treatment

NCT04298034
View directory record Official record
Conditions
Preeclampsia, Hypertension in Pregnancy
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Antihypertensive Therapy Adherence

NCT04029883
View directory record Official record
Conditions
Hypertension, Medication Adherence
Interventions
Text Message, Behavior Economic Incentive
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses

NCT00246519
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
17 Years to 65 Years
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

NCT00716079
View directory record Official record
Conditions
Intracerebral Hemorrhage, Stroke, Hypertension
Interventions
Blood pressure management policies
Other
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
2,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Not applicable Interventional Results available

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

NCT02439749
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
30
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women

NCT04530916
View directory record Official record
Conditions
Hypertension, Aging, Endothelial Dysfunction, Men
Interventions
Blueberry Powder, Placebo Powder
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 2, 2026, 4:10 AM EDT
Completed Phase 2 Interventional

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

NCT06272487
View directory record Official record
Conditions
High Cardiovascular Risk, Hypertension
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
139
States / cities
Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 2, 2026, 4:10 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

NCT03179163
View directory record Official record
Conditions
Hypertension,Essential
Interventions
Captopril Pill, Enalapril Pill, Hydrochlorothiazide
Drug
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 2, 2026, 4:10 AM EDT